Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier
Nicolas Santander, Carlos O. Lizama, Eman Meky, Gabriel L. McKinsey, Bongnam Jung, Dean Sheppard, Christer Betsholtz, Thomas D. Arnold
Nicolas Santander, Carlos O. Lizama, Eman Meky, Gabriel L. McKinsey, Bongnam Jung, Dean Sheppard, Christer Betsholtz, Thomas D. Arnold
View: Text | PDF
Research Article Angiogenesis Development

Lack of Flvcr2 impairs brain angiogenesis without affecting the blood-brain barrier

  • Text
  • PDF
Abstract

Fowler syndrome is a rare autosomal recessive brain vascular disorder caused by mutation in FLVCR2 in humans. The disease occurs during a critical period of brain vascular development, is characterized by glomeruloid vasculopathy and hydrocephalus, and is almost invariably prenatally fatal. Here, we sought to gain insights into the process of brain vascularization and the pathogenesis of Fowler syndrome by inactivating Flvcr2 in mice. We showed that Flvcr2 was necessary for angiogenic sprouting in the brain, but surprisingly dispensable for maintaining the blood-brain barrier. Endothelial cells lacking Flvcr2 had altered expression of angiogenic factors, failed to adopt tip cell properties, and displayed reduced sprouting, leading to vascular malformations similar to those seen in humans with Fowler syndrome. Brain hypovascularization was associated with hypoxia and tissue infarction, ultimately causing hydrocephalus and death of mutant animals. Strikingly, despite severe vascular anomalies and brain tissue infarction, the blood-brain barrier was maintained in Flvcr2 mutant mice. Our Fowler syndrome model therefore defined the pathobiology of this disease and provided new insights into brain angiogenesis by showing uncoupling of vessel morphogenesis and blood-brain barrier formation.

Authors

Nicolas Santander, Carlos O. Lizama, Eman Meky, Gabriel L. McKinsey, Bongnam Jung, Dean Sheppard, Christer Betsholtz, Thomas D. Arnold

×

Figure 1

Flvcr2 inactivation in mice models human PVHH.

Options: View larger image (or click on image) Download as PowerPoint

Flvcr2 inactivation in mice models human PVHH.
(A) Coronal sections thr...
(A) Coronal sections through the lateral ventricles at the indicated embryonic stages were stained to visualize GFP and the endothelial cell marker CD31. Dotted violet lines delineate the ventricles. Boxed areas show magnified areas of the LGE. Numbers indicate the number of embryos with the represented phenotype. Scale bars: 200 μm. (B) Vessels in embryonic brains were stained with CD31 and ERG antibodies. A representative dilated vessel (from 5 E14.5 embryos with the phenotype) in the Flvcr2GFP/GFP GE is shown. L, vessel lumen. Scale bar: 50 μm. (C) Fraction of brain area covered by CD31+ cells. ***P < 0.001, t test. E12.5, n = 4; E14.5, n = 6; E18.5, n = 7–8. (D) Thickness of periventricular vessels. ***P < 0.001, t test. E12.5, n = 4; E14.5, n = 6; E18.5, n = 7–8. (E) Fluorescence intensity profile of CD31 in the LGE of Flvcr2+/GFP and Flvcr2GFP/GFP embryos at E14.5 expressed as mean (solid line) + SEM (shaded area). n = 6. (F) Coronal sections of E14.5 brains were obtained from embryos with constitutive (Flvcr2ΔEC) deletion of Flvcr2 in endothelial cells and stained for GFP and CD31. Scale bars: 200 μm. (G) Coronal sections of E18.5 brains were stained for SOX9 (a marker of apical neuro/glia progenitors at this stage) to reveal the ventricle wall. Scale bar: 500 μm. (H) Ventricle area was compared in mutants and controls. *P < 0.05, t test. Flvcr2+/GFP, n = 8; Flvcr2GFP/GFP, n = 7.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts